The FIELD study investigators. Lancet 2005; available at: http://www.lancet.com.

End point Placebo (n=4900), n (%)

Fenofibrate (n=4895), n (%)

HR(95% CI)

p

CHD death/nonfatal MI

288 (6) 256 (5) 0.89(0.75-1.05)

0.16

CHD death 93 (2) 110 (2) 1.19(0.90-1.57)

0.22

Nonfatal MI 207 (4) 158 (3) 0.76(0.62-0.94)

0.010

FIELD: Primary outcome

The FIELD study investigators. Lancet 2005; available at: http://www.lancet.com.

End point Placebo (n=4900), n (%)

Fenofibrate (n=4895), n (%)

HR(95% CI)

p

Total CV events 683 (14) 612 (13) 0.89(0.80-0.99)

0.035

CV mortality 127 (3) 140 (3) 1.11(0.87-1.41)

0.41

Total mortality 323 (7) 356 (7) 1.11(0.95-1.29)

0.18

Stroke 175 (4) 158 (3) 0.90(0.73-1.12)

0.36

Coronary revascularization

364 (7) 290 (6) 0.79(0.68-0.93)

0.003

All revascularization

471 (10) 380 (8) 0.80(0.70-0.92)

0.001

FIELD: Secondary outcomes